nodes	percent_of_prediction	percent_of_DWPC	metapath
Modafinil—CYP1A2—Anagrelide—hematologic cancer	0.0319	0.0473	CbGbCtD
Modafinil—CYP2B6—Thiotepa—hematologic cancer	0.0312	0.0463	CbGbCtD
Modafinil—CYP2C9—Bexarotene—hematologic cancer	0.0199	0.0295	CbGbCtD
Modafinil—CYP2B6—Ifosfamide—hematologic cancer	0.0177	0.0263	CbGbCtD
Modafinil—CYP3A5—Daunorubicin—hematologic cancer	0.0174	0.0258	CbGbCtD
Modafinil—CYP1A2—Carmustine—hematologic cancer	0.0168	0.0248	CbGbCtD
Modafinil—CYP2C9—Idarubicin—hematologic cancer	0.0165	0.0245	CbGbCtD
Modafinil—CYP3A5—Thalidomide—hematologic cancer	0.0159	0.0235	CbGbCtD
Modafinil—CYP2B6—Nilotinib—hematologic cancer	0.0154	0.0228	CbGbCtD
Modafinil—CYP3A5—Teniposide—hematologic cancer	0.0151	0.0224	CbGbCtD
Modafinil—CYP2C19—Bortezomib—hematologic cancer	0.0147	0.0218	CbGbCtD
Modafinil—CYP1A2—Methoxsalen—hematologic cancer	0.0142	0.0211	CbGbCtD
Modafinil—CYP3A5—Ifosfamide—hematologic cancer	0.014	0.0207	CbGbCtD
Modafinil—CYP1A2—Bortezomib—hematologic cancer	0.0135	0.0201	CbGbCtD
Modafinil—CYP3A5—Imatinib—hematologic cancer	0.0133	0.0198	CbGbCtD
Modafinil—CYP1A2—Daunorubicin—hematologic cancer	0.013	0.0192	CbGbCtD
Modafinil—CYP2C19—Thalidomide—hematologic cancer	0.0128	0.019	CbGbCtD
Modafinil—CYP1A2—Alitretinoin—hematologic cancer	0.0127	0.0188	CbGbCtD
Modafinil—CYP2C9—Bortezomib—hematologic cancer	0.0122	0.0181	CbGbCtD
Modafinil—CYP2C19—Teniposide—hematologic cancer	0.0122	0.0181	CbGbCtD
Modafinil—CYP1A2—Thalidomide—hematologic cancer	0.0118	0.0175	CbGbCtD
Modafinil—CYP3A4—Bexarotene—hematologic cancer	0.0116	0.0172	CbGbCtD
Modafinil—CYP2C19—Ifosfamide—hematologic cancer	0.0113	0.0167	CbGbCtD
Modafinil—CYP3A4—Lomustine—hematologic cancer	0.0108	0.016	CbGbCtD
Modafinil—CYP3A4—Busulfan—hematologic cancer	0.0108	0.016	CbGbCtD
Modafinil—CYP2C19—Imatinib—hematologic cancer	0.0108	0.016	CbGbCtD
Modafinil—CYP3A5—Dasatinib—hematologic cancer	0.0107	0.0159	CbGbCtD
Modafinil—CYP2C9—Thalidomide—hematologic cancer	0.0106	0.0158	CbGbCtD
Modafinil—CYP2B6—Irinotecan—hematologic cancer	0.0106	0.0157	CbGbCtD
Modafinil—CYP1A2—Dacarbazine—hematologic cancer	0.0102	0.0151	CbGbCtD
Modafinil—CYP2C9—Teniposide—hematologic cancer	0.0101	0.015	CbGbCtD
Modafinil—CYP1A2—Imatinib—hematologic cancer	0.00993	0.0147	CbGbCtD
Modafinil—CYP3A4—Thiotepa—hematologic cancer	0.0096	0.0142	CbGbCtD
Modafinil—CYP2C9—Ifosfamide—hematologic cancer	0.00936	0.0139	CbGbCtD
Modafinil—CYP2C9—Imatinib—hematologic cancer	0.00894	0.0133	CbGbCtD
Modafinil—CYP2B6—Cisplatin—hematologic cancer	0.00862	0.0128	CbGbCtD
Modafinil—CYP3A5—Irinotecan—hematologic cancer	0.00833	0.0124	CbGbCtD
Modafinil—CYP2C9—Nilotinib—hematologic cancer	0.00813	0.0121	CbGbCtD
Modafinil—CYP1A2—Dasatinib—hematologic cancer	0.00797	0.0118	CbGbCtD
Modafinil—CYP3A4—Methoxsalen—hematologic cancer	0.00746	0.0111	CbGbCtD
Modafinil—CYP3A5—Vincristine—hematologic cancer	0.00728	0.0108	CbGbCtD
Modafinil—CYP3A4—Bortezomib—hematologic cancer	0.0071	0.0105	CbGbCtD
Modafinil—CYP2C19—Prednisone—hematologic cancer	0.00709	0.0105	CbGbCtD
Modafinil—CYP2B6—Dexamethasone—hematologic cancer	0.00696	0.0103	CbGbCtD
Modafinil—CYP3A4—Daunorubicin—hematologic cancer	0.00679	0.0101	CbGbCtD
Modafinil—CYP3A5—Etoposide—hematologic cancer	0.00667	0.00989	CbGbCtD
Modafinil—CYP3A4—Cytarabine—hematologic cancer	0.00599	0.00888	CbGbCtD
Modafinil—CYP3A4—Teniposide—hematologic cancer	0.0059	0.00875	CbGbCtD
Modafinil—CYP2B6—Doxorubicin—hematologic cancer	0.00578	0.00857	CbGbCtD
Modafinil—CYP3A5—Dexamethasone—hematologic cancer	0.00549	0.00814	CbGbCtD
Modafinil—CYP3A4—Ifosfamide—hematologic cancer	0.00544	0.00807	CbGbCtD
Modafinil—CYP3A4—Imatinib—hematologic cancer	0.0052	0.00771	CbGbCtD
Modafinil—CYP1A2—Etoposide—hematologic cancer	0.00497	0.00736	CbGbCtD
Modafinil—CYP3A4—Ruxolitinib—hematologic cancer	0.0049	0.00726	CbGbCtD
Modafinil—CYP3A4—Nilotinib—hematologic cancer	0.00473	0.00701	CbGbCtD
Modafinil—CYP3A4—Vinorelbine—hematologic cancer	0.00469	0.00695	CbGbCtD
Modafinil—CYP2C9—Cisplatin—hematologic cancer	0.00455	0.00675	CbGbCtD
Modafinil—CYP2C19—Dexamethasone—hematologic cancer	0.00443	0.00656	CbGbCtD
Modafinil—CYP3A4—Triamcinolone—hematologic cancer	0.00429	0.00636	CbGbCtD
Modafinil—CYP3A4—Dasatinib—hematologic cancer	0.00418	0.00619	CbGbCtD
Modafinil—CYP3A4—Mitoxantrone—hematologic cancer	0.00413	0.00612	CbGbCtD
Modafinil—CYP2C9—Dexamethasone—hematologic cancer	0.00368	0.00546	CbGbCtD
Modafinil—CYP3A4—Betamethasone—hematologic cancer	0.00368	0.00545	CbGbCtD
Modafinil—CYP3A4—Prednisolone—hematologic cancer	0.00363	0.00538	CbGbCtD
Modafinil—CYP3A4—Prednisone—hematologic cancer	0.00343	0.00508	CbGbCtD
Modafinil—CYP3A4—Irinotecan—hematologic cancer	0.00325	0.00482	CbGbCtD
Modafinil—CYP3A4—Vinblastine—hematologic cancer	0.00289	0.00428	CbGbCtD
Modafinil—CYP3A4—Vincristine—hematologic cancer	0.00284	0.00421	CbGbCtD
Modafinil—CYP3A4—Etoposide—hematologic cancer	0.0026	0.00386	CbGbCtD
Modafinil—CYP3A4—Dexamethasone—hematologic cancer	0.00214	0.00317	CbGbCtD
Modafinil—CYP3A4—Doxorubicin—hematologic cancer	0.00177	0.00263	CbGbCtD
Modafinil—Phenoxybenzamine—SLC22A1—hematologic cancer	0.000114	0.154	CrCbGaD
Modafinil—Diphenhydramine—SLC22A1—hematologic cancer	9.6e-05	0.129	CrCbGaD
Modafinil—Fosphenytoin—ALB—hematologic cancer	8.45e-05	0.114	CrCbGaD
Modafinil—Fenoprofen—ALB—hematologic cancer	6.72e-05	0.0904	CrCbGaD
Modafinil—Phenprocoumon—ALB—hematologic cancer	5.79e-05	0.0779	CrCbGaD
Modafinil—Oxcarbazepine—ALB—hematologic cancer	5.63e-05	0.0758	CrCbGaD
Modafinil—Warfarin—ALB—hematologic cancer	5.14e-05	0.0691	CrCbGaD
Modafinil—Ketoprofen—ALB—hematologic cancer	3.97e-05	0.0534	CrCbGaD
Modafinil—Fentanyl—ABCB1—hematologic cancer	3.93e-05	0.0529	CrCbGaD
Modafinil—Phenytoin—ALB—hematologic cancer	3.73e-05	0.0502	CrCbGaD
Modafinil—Carbamazepine—ABCB1—hematologic cancer	3.67e-05	0.0493	CrCbGaD
Modafinil—Phenytoin—ABCB1—hematologic cancer	3.56e-05	0.0479	CrCbGaD
Modafinil—Methadone—ABCB1—hematologic cancer	2.69e-05	0.0362	CrCbGaD
Modafinil—Rash—Cisplatin—hematologic cancer	2.57e-05	9.17e-05	CcSEcCtD
Modafinil—Dermatitis—Cisplatin—hematologic cancer	2.57e-05	9.16e-05	CcSEcCtD
Modafinil—Malnutrition—Epirubicin—hematologic cancer	2.57e-05	9.15e-05	CcSEcCtD
Modafinil—Diarrhoea—Etoposide—hematologic cancer	2.56e-05	9.12e-05	CcSEcCtD
Modafinil—Anorexia—Prednisone—hematologic cancer	2.56e-05	9.1e-05	CcSEcCtD
Modafinil—Ill-defined disorder—Methotrexate—hematologic cancer	2.55e-05	9.07e-05	CcSEcCtD
Modafinil—Anaemia—Methotrexate—hematologic cancer	2.54e-05	9.04e-05	CcSEcCtD
Modafinil—Feeling abnormal—Dexamethasone—hematologic cancer	2.54e-05	9.04e-05	CcSEcCtD
Modafinil—Feeling abnormal—Betamethasone—hematologic cancer	2.54e-05	9.04e-05	CcSEcCtD
Modafinil—Cardiac disorder—Doxorubicin—hematologic cancer	2.53e-05	9.03e-05	CcSEcCtD
Modafinil—Flatulence—Epirubicin—hematologic cancer	2.53e-05	9.02e-05	CcSEcCtD
Modafinil—Tension—Epirubicin—hematologic cancer	2.52e-05	8.98e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.52e-05	8.97e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Betamethasone—hematologic cancer	2.52e-05	8.97e-05	CcSEcCtD
Modafinil—Dysgeusia—Epirubicin—hematologic cancer	2.52e-05	8.96e-05	CcSEcCtD
Modafinil—Hypersensitivity—Triamcinolone—hematologic cancer	2.5e-05	8.9e-05	CcSEcCtD
Modafinil—Nervousness—Epirubicin—hematologic cancer	2.5e-05	8.89e-05	CcSEcCtD
Modafinil—Back pain—Epirubicin—hematologic cancer	2.48e-05	8.85e-05	CcSEcCtD
Modafinil—Angiopathy—Doxorubicin—hematologic cancer	2.48e-05	8.83e-05	CcSEcCtD
Modafinil—Malaise—Methotrexate—hematologic cancer	2.48e-05	8.82e-05	CcSEcCtD
Modafinil—Dizziness—Etoposide—hematologic cancer	2.47e-05	8.81e-05	CcSEcCtD
Modafinil—Muscle spasms—Epirubicin—hematologic cancer	2.47e-05	8.8e-05	CcSEcCtD
Modafinil—Immune system disorder—Doxorubicin—hematologic cancer	2.47e-05	8.79e-05	CcSEcCtD
Modafinil—Vertigo—Methotrexate—hematologic cancer	2.47e-05	8.79e-05	CcSEcCtD
Modafinil—Mediastinal disorder—Doxorubicin—hematologic cancer	2.46e-05	8.77e-05	CcSEcCtD
Modafinil—Chills—Doxorubicin—hematologic cancer	2.45e-05	8.73e-05	CcSEcCtD
Modafinil—Urticaria—Dexamethasone—hematologic cancer	2.45e-05	8.71e-05	CcSEcCtD
Modafinil—Urticaria—Betamethasone—hematologic cancer	2.45e-05	8.71e-05	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.44e-05	8.7e-05	CcSEcCtD
Modafinil—Dizziness—Prednisolone—hematologic cancer	2.44e-05	8.69e-05	CcSEcCtD
Modafinil—Arrhythmia—Doxorubicin—hematologic cancer	2.44e-05	8.69e-05	CcSEcCtD
Modafinil—Asthenia—Triamcinolone—hematologic cancer	2.43e-05	8.67e-05	CcSEcCtD
Modafinil—Abdominal pain—Betamethasone—hematologic cancer	2.43e-05	8.67e-05	CcSEcCtD
Modafinil—Body temperature increased—Dexamethasone—hematologic cancer	2.43e-05	8.67e-05	CcSEcCtD
Modafinil—Abdominal pain—Dexamethasone—hematologic cancer	2.43e-05	8.67e-05	CcSEcCtD
Modafinil—Body temperature increased—Betamethasone—hematologic cancer	2.43e-05	8.67e-05	CcSEcCtD
Modafinil—Nausea—Cisplatin—hematologic cancer	2.43e-05	8.64e-05	CcSEcCtD
Modafinil—Insomnia—Prednisone—hematologic cancer	2.42e-05	8.64e-05	CcSEcCtD
Modafinil—Paraesthesia—Prednisone—hematologic cancer	2.41e-05	8.57e-05	CcSEcCtD
Modafinil—Pruritus—Triamcinolone—hematologic cancer	2.4e-05	8.55e-05	CcSEcCtD
Modafinil—Cough—Methotrexate—hematologic cancer	2.4e-05	8.53e-05	CcSEcCtD
Modafinil—Mental disorder—Doxorubicin—hematologic cancer	2.39e-05	8.52e-05	CcSEcCtD
Modafinil—Ill-defined disorder—Epirubicin—hematologic cancer	2.38e-05	8.49e-05	CcSEcCtD
Modafinil—Convulsion—Methotrexate—hematologic cancer	2.38e-05	8.47e-05	CcSEcCtD
Modafinil—Vomiting—Etoposide—hematologic cancer	2.38e-05	8.47e-05	CcSEcCtD
Modafinil—Malnutrition—Doxorubicin—hematologic cancer	2.38e-05	8.47e-05	CcSEcCtD
Modafinil—Anaemia—Epirubicin—hematologic cancer	2.37e-05	8.46e-05	CcSEcCtD
Modafinil—Agitation—Epirubicin—hematologic cancer	2.36e-05	8.41e-05	CcSEcCtD
Modafinil—Dyspepsia—Prednisone—hematologic cancer	2.36e-05	8.41e-05	CcSEcCtD
Modafinil—Rash—Etoposide—hematologic cancer	2.36e-05	8.4e-05	CcSEcCtD
Modafinil—Dermatitis—Etoposide—hematologic cancer	2.36e-05	8.39e-05	CcSEcCtD
Modafinil—Headache—Etoposide—hematologic cancer	2.34e-05	8.35e-05	CcSEcCtD
Modafinil—Flatulence—Doxorubicin—hematologic cancer	2.34e-05	8.34e-05	CcSEcCtD
Modafinil—Chest pain—Methotrexate—hematologic cancer	2.34e-05	8.33e-05	CcSEcCtD
Modafinil—Arthralgia—Methotrexate—hematologic cancer	2.34e-05	8.33e-05	CcSEcCtD
Modafinil—Myalgia—Methotrexate—hematologic cancer	2.34e-05	8.33e-05	CcSEcCtD
Modafinil—Tension—Doxorubicin—hematologic cancer	2.33e-05	8.31e-05	CcSEcCtD
Modafinil—Decreased appetite—Prednisone—hematologic cancer	2.33e-05	8.3e-05	CcSEcCtD
Modafinil—Dysgeusia—Doxorubicin—hematologic cancer	2.33e-05	8.29e-05	CcSEcCtD
Modafinil—Rash—Prednisolone—hematologic cancer	2.33e-05	8.29e-05	CcSEcCtD
Modafinil—Dermatitis—Prednisolone—hematologic cancer	2.32e-05	8.28e-05	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.32e-05	8.27e-05	CcSEcCtD
Modafinil—Malaise—Epirubicin—hematologic cancer	2.32e-05	8.25e-05	CcSEcCtD
Modafinil—Fatigue—Prednisone—hematologic cancer	2.31e-05	8.23e-05	CcSEcCtD
Modafinil—Headache—Prednisolone—hematologic cancer	2.31e-05	8.23e-05	CcSEcCtD
Modafinil—Discomfort—Methotrexate—hematologic cancer	2.31e-05	8.23e-05	CcSEcCtD
Modafinil—Nervousness—Doxorubicin—hematologic cancer	2.31e-05	8.22e-05	CcSEcCtD
Modafinil—Vertigo—Epirubicin—hematologic cancer	2.31e-05	8.22e-05	CcSEcCtD
Modafinil—Syncope—Epirubicin—hematologic cancer	2.3e-05	8.21e-05	CcSEcCtD
Modafinil—Back pain—Doxorubicin—hematologic cancer	2.3e-05	8.19e-05	CcSEcCtD
Modafinil—Constipation—Prednisone—hematologic cancer	2.29e-05	8.17e-05	CcSEcCtD
Modafinil—Muscle spasms—Doxorubicin—hematologic cancer	2.29e-05	8.14e-05	CcSEcCtD
Modafinil—Palpitations—Epirubicin—hematologic cancer	2.27e-05	8.09e-05	CcSEcCtD
Modafinil—Confusional state—Methotrexate—hematologic cancer	2.26e-05	8.05e-05	CcSEcCtD
Modafinil—Loss of consciousness—Epirubicin—hematologic cancer	2.26e-05	8.04e-05	CcSEcCtD
Modafinil—Dizziness—Triamcinolone—hematologic cancer	2.24e-05	7.99e-05	CcSEcCtD
Modafinil—Cough—Epirubicin—hematologic cancer	2.24e-05	7.99e-05	CcSEcCtD
Modafinil—Anaphylactic shock—Methotrexate—hematologic cancer	2.24e-05	7.98e-05	CcSEcCtD
Modafinil—Convulsion—Epirubicin—hematologic cancer	2.23e-05	7.93e-05	CcSEcCtD
Modafinil—Infection—Methotrexate—hematologic cancer	2.23e-05	7.93e-05	CcSEcCtD
Modafinil—Nausea—Etoposide—hematologic cancer	2.22e-05	7.91e-05	CcSEcCtD
Modafinil—Hypertension—Epirubicin—hematologic cancer	2.22e-05	7.9e-05	CcSEcCtD
Modafinil—Feeling abnormal—Prednisone—hematologic cancer	2.21e-05	7.87e-05	CcSEcCtD
Modafinil—Asthenia—Betamethasone—hematologic cancer	2.21e-05	7.87e-05	CcSEcCtD
Modafinil—Asthenia—Dexamethasone—hematologic cancer	2.21e-05	7.87e-05	CcSEcCtD
Modafinil—Ill-defined disorder—Doxorubicin—hematologic cancer	2.21e-05	7.86e-05	CcSEcCtD
Modafinil—Nervous system disorder—Methotrexate—hematologic cancer	2.2e-05	7.83e-05	CcSEcCtD
Modafinil—Anaemia—Doxorubicin—hematologic cancer	2.2e-05	7.83e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Prednisone—hematologic cancer	2.19e-05	7.81e-05	CcSEcCtD
Modafinil—Nausea—Prednisolone—hematologic cancer	2.19e-05	7.81e-05	CcSEcCtD
Modafinil—Myalgia—Epirubicin—hematologic cancer	2.19e-05	7.79e-05	CcSEcCtD
Modafinil—Arthralgia—Epirubicin—hematologic cancer	2.19e-05	7.79e-05	CcSEcCtD
Modafinil—Chest pain—Epirubicin—hematologic cancer	2.19e-05	7.79e-05	CcSEcCtD
Modafinil—Agitation—Doxorubicin—hematologic cancer	2.18e-05	7.78e-05	CcSEcCtD
Modafinil—Anxiety—Epirubicin—hematologic cancer	2.18e-05	7.76e-05	CcSEcCtD
Modafinil—Pruritus—Betamethasone—hematologic cancer	2.18e-05	7.76e-05	CcSEcCtD
Modafinil—Pruritus—Dexamethasone—hematologic cancer	2.18e-05	7.76e-05	CcSEcCtD
Modafinil—Skin disorder—Methotrexate—hematologic cancer	2.18e-05	7.75e-05	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.17e-05	7.74e-05	CcSEcCtD
Modafinil—Hyperhidrosis—Methotrexate—hematologic cancer	2.17e-05	7.72e-05	CcSEcCtD
Modafinil—Discomfort—Epirubicin—hematologic cancer	2.16e-05	7.7e-05	CcSEcCtD
Modafinil—Vomiting—Triamcinolone—hematologic cancer	2.16e-05	7.68e-05	CcSEcCtD
Modafinil—Malaise—Doxorubicin—hematologic cancer	2.14e-05	7.64e-05	CcSEcCtD
Modafinil—Rash—Triamcinolone—hematologic cancer	2.14e-05	7.62e-05	CcSEcCtD
Modafinil—Dry mouth—Epirubicin—hematologic cancer	2.14e-05	7.62e-05	CcSEcCtD
Modafinil—Dermatitis—Triamcinolone—hematologic cancer	2.14e-05	7.61e-05	CcSEcCtD
Modafinil—Vertigo—Doxorubicin—hematologic cancer	2.14e-05	7.61e-05	CcSEcCtD
Modafinil—Anorexia—Methotrexate—hematologic cancer	2.14e-05	7.61e-05	CcSEcCtD
Modafinil—Syncope—Doxorubicin—hematologic cancer	2.13e-05	7.59e-05	CcSEcCtD
Modafinil—Urticaria—Prednisone—hematologic cancer	2.13e-05	7.59e-05	CcSEcCtD
Modafinil—Headache—Triamcinolone—hematologic cancer	2.13e-05	7.57e-05	CcSEcCtD
Modafinil—Abdominal pain—Prednisone—hematologic cancer	2.12e-05	7.55e-05	CcSEcCtD
Modafinil—Body temperature increased—Prednisone—hematologic cancer	2.12e-05	7.55e-05	CcSEcCtD
Modafinil—Confusional state—Epirubicin—hematologic cancer	2.11e-05	7.53e-05	CcSEcCtD
Modafinil—Diarrhoea—Betamethasone—hematologic cancer	2.11e-05	7.5e-05	CcSEcCtD
Modafinil—Diarrhoea—Dexamethasone—hematologic cancer	2.11e-05	7.5e-05	CcSEcCtD
Modafinil—Palpitations—Doxorubicin—hematologic cancer	2.1e-05	7.48e-05	CcSEcCtD
Modafinil—Oedema—Epirubicin—hematologic cancer	2.1e-05	7.47e-05	CcSEcCtD
Modafinil—Anaphylactic shock—Epirubicin—hematologic cancer	2.1e-05	7.47e-05	CcSEcCtD
Modafinil—Hypotension—Methotrexate—hematologic cancer	2.09e-05	7.46e-05	CcSEcCtD
Modafinil—Loss of consciousness—Doxorubicin—hematologic cancer	2.09e-05	7.44e-05	CcSEcCtD
Modafinil—Infection—Epirubicin—hematologic cancer	2.08e-05	7.42e-05	CcSEcCtD
Modafinil—Cough—Doxorubicin—hematologic cancer	2.07e-05	7.39e-05	CcSEcCtD
Modafinil—Shock—Epirubicin—hematologic cancer	2.06e-05	7.35e-05	CcSEcCtD
Modafinil—Convulsion—Doxorubicin—hematologic cancer	2.06e-05	7.34e-05	CcSEcCtD
Modafinil—Nervous system disorder—Epirubicin—hematologic cancer	2.06e-05	7.32e-05	CcSEcCtD
Modafinil—Hypertension—Doxorubicin—hematologic cancer	2.05e-05	7.31e-05	CcSEcCtD
Modafinil—Tachycardia—Epirubicin—hematologic cancer	2.05e-05	7.29e-05	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.04e-05	7.27e-05	CcSEcCtD
Modafinil—Skin disorder—Epirubicin—hematologic cancer	2.04e-05	7.25e-05	CcSEcCtD
Modafinil—Dizziness—Betamethasone—hematologic cancer	2.04e-05	7.25e-05	CcSEcCtD
Modafinil—Dizziness—Dexamethasone—hematologic cancer	2.04e-05	7.25e-05	CcSEcCtD
Modafinil—Hyperhidrosis—Epirubicin—hematologic cancer	2.03e-05	7.22e-05	CcSEcCtD
Modafinil—Insomnia—Methotrexate—hematologic cancer	2.03e-05	7.22e-05	CcSEcCtD
Modafinil—Myalgia—Doxorubicin—hematologic cancer	2.02e-05	7.21e-05	CcSEcCtD
Modafinil—Chest pain—Doxorubicin—hematologic cancer	2.02e-05	7.21e-05	CcSEcCtD
Modafinil—Arthralgia—Doxorubicin—hematologic cancer	2.02e-05	7.21e-05	CcSEcCtD
Modafinil—Anxiety—Doxorubicin—hematologic cancer	2.02e-05	7.18e-05	CcSEcCtD
Modafinil—Nausea—Triamcinolone—hematologic cancer	2.02e-05	7.18e-05	CcSEcCtD
Modafinil—Paraesthesia—Methotrexate—hematologic cancer	2.01e-05	7.17e-05	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.01e-05	7.16e-05	CcSEcCtD
Modafinil—Discomfort—Doxorubicin—hematologic cancer	2e-05	7.12e-05	CcSEcCtD
Modafinil—Anorexia—Epirubicin—hematologic cancer	2e-05	7.12e-05	CcSEcCtD
Modafinil—Dyspnoea—Methotrexate—hematologic cancer	2e-05	7.12e-05	CcSEcCtD
Modafinil—Somnolence—Methotrexate—hematologic cancer	1.99e-05	7.09e-05	CcSEcCtD
Modafinil—Dry mouth—Doxorubicin—hematologic cancer	1.98e-05	7.05e-05	CcSEcCtD
Modafinil—Hypersensitivity—Prednisone—hematologic cancer	1.98e-05	7.04e-05	CcSEcCtD
Modafinil—Dyspepsia—Methotrexate—hematologic cancer	1.97e-05	7.03e-05	CcSEcCtD
Modafinil—Hypotension—Epirubicin—hematologic cancer	1.96e-05	6.98e-05	CcSEcCtD
Modafinil—Vomiting—Dexamethasone—hematologic cancer	1.96e-05	6.97e-05	CcSEcCtD
Modafinil—Vomiting—Betamethasone—hematologic cancer	1.96e-05	6.97e-05	CcSEcCtD
Modafinil—Confusional state—Doxorubicin—hematologic cancer	1.96e-05	6.97e-05	CcSEcCtD
Modafinil—Decreased appetite—Methotrexate—hematologic cancer	1.95e-05	6.94e-05	CcSEcCtD
Modafinil—Rash—Betamethasone—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Rash—Dexamethasone—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Oedema—Doxorubicin—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Anaphylactic shock—Doxorubicin—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Dermatitis—Betamethasone—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Dermatitis—Dexamethasone—hematologic cancer	1.94e-05	6.91e-05	CcSEcCtD
Modafinil—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.93e-05	6.89e-05	CcSEcCtD
Modafinil—Fatigue—Methotrexate—hematologic cancer	1.93e-05	6.88e-05	CcSEcCtD
Modafinil—Headache—Dexamethasone—hematologic cancer	1.93e-05	6.87e-05	CcSEcCtD
Modafinil—Headache—Betamethasone—hematologic cancer	1.93e-05	6.87e-05	CcSEcCtD
Modafinil—Infection—Doxorubicin—hematologic cancer	1.93e-05	6.87e-05	CcSEcCtD
Modafinil—Asthenia—Prednisone—hematologic cancer	1.92e-05	6.85e-05	CcSEcCtD
Modafinil—Pain—Methotrexate—hematologic cancer	1.92e-05	6.82e-05	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.91e-05	6.8e-05	CcSEcCtD
Modafinil—Shock—Doxorubicin—hematologic cancer	1.91e-05	6.8e-05	CcSEcCtD
Modafinil—Nervous system disorder—Doxorubicin—hematologic cancer	1.9e-05	6.78e-05	CcSEcCtD
Modafinil—Pruritus—Prednisone—hematologic cancer	1.9e-05	6.76e-05	CcSEcCtD
Modafinil—Insomnia—Epirubicin—hematologic cancer	1.9e-05	6.76e-05	CcSEcCtD
Modafinil—Tachycardia—Doxorubicin—hematologic cancer	1.89e-05	6.74e-05	CcSEcCtD
Modafinil—Skin disorder—Doxorubicin—hematologic cancer	1.88e-05	6.71e-05	CcSEcCtD
Modafinil—Paraesthesia—Epirubicin—hematologic cancer	1.88e-05	6.71e-05	CcSEcCtD
Modafinil—Hyperhidrosis—Doxorubicin—hematologic cancer	1.88e-05	6.68e-05	CcSEcCtD
Modafinil—Dyspnoea—Epirubicin—hematologic cancer	1.87e-05	6.66e-05	CcSEcCtD
Modafinil—Somnolence—Epirubicin—hematologic cancer	1.86e-05	6.64e-05	CcSEcCtD
Modafinil—Anorexia—Doxorubicin—hematologic cancer	1.85e-05	6.59e-05	CcSEcCtD
Modafinil—Feeling abnormal—Methotrexate—hematologic cancer	1.85e-05	6.58e-05	CcSEcCtD
Modafinil—Dyspepsia—Epirubicin—hematologic cancer	1.85e-05	6.57e-05	CcSEcCtD
Modafinil—Diarrhoea—Prednisone—hematologic cancer	1.83e-05	6.53e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Methotrexate—hematologic cancer	1.83e-05	6.53e-05	CcSEcCtD
Modafinil—Nausea—Dexamethasone—hematologic cancer	1.83e-05	6.51e-05	CcSEcCtD
Modafinil—Nausea—Betamethasone—hematologic cancer	1.83e-05	6.51e-05	CcSEcCtD
Modafinil—Decreased appetite—Epirubicin—hematologic cancer	1.82e-05	6.49e-05	CcSEcCtD
Modafinil—Hypotension—Doxorubicin—hematologic cancer	1.81e-05	6.46e-05	CcSEcCtD
Modafinil—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.81e-05	6.45e-05	CcSEcCtD
Modafinil—Fatigue—Epirubicin—hematologic cancer	1.81e-05	6.44e-05	CcSEcCtD
Modafinil—Pain—Epirubicin—hematologic cancer	1.79e-05	6.39e-05	CcSEcCtD
Modafinil—Constipation—Epirubicin—hematologic cancer	1.79e-05	6.39e-05	CcSEcCtD
Modafinil—Urticaria—Methotrexate—hematologic cancer	1.78e-05	6.34e-05	CcSEcCtD
Modafinil—Dizziness—Prednisone—hematologic cancer	1.77e-05	6.31e-05	CcSEcCtD
Modafinil—Body temperature increased—Methotrexate—hematologic cancer	1.77e-05	6.31e-05	CcSEcCtD
Modafinil—Abdominal pain—Methotrexate—hematologic cancer	1.77e-05	6.31e-05	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.77e-05	6.3e-05	CcSEcCtD
Modafinil—Insomnia—Doxorubicin—hematologic cancer	1.75e-05	6.25e-05	CcSEcCtD
Modafinil—Paraesthesia—Doxorubicin—hematologic cancer	1.74e-05	6.21e-05	CcSEcCtD
Modafinil—Dyspnoea—Doxorubicin—hematologic cancer	1.73e-05	6.16e-05	CcSEcCtD
Modafinil—Feeling abnormal—Epirubicin—hematologic cancer	1.73e-05	6.15e-05	CcSEcCtD
Modafinil—Somnolence—Doxorubicin—hematologic cancer	1.72e-05	6.14e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Epirubicin—hematologic cancer	1.71e-05	6.11e-05	CcSEcCtD
Modafinil—Dyspepsia—Doxorubicin—hematologic cancer	1.71e-05	6.08e-05	CcSEcCtD
Modafinil—Vomiting—Prednisone—hematologic cancer	1.7e-05	6.07e-05	CcSEcCtD
Modafinil—Rash—Prednisone—hematologic cancer	1.69e-05	6.02e-05	CcSEcCtD
Modafinil—Dermatitis—Prednisone—hematologic cancer	1.69e-05	6.02e-05	CcSEcCtD
Modafinil—Decreased appetite—Doxorubicin—hematologic cancer	1.69e-05	6.01e-05	CcSEcCtD
Modafinil—Headache—Prednisone—hematologic cancer	1.68e-05	5.98e-05	CcSEcCtD
Modafinil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.67e-05	5.97e-05	CcSEcCtD
Modafinil—Fatigue—Doxorubicin—hematologic cancer	1.67e-05	5.96e-05	CcSEcCtD
Modafinil—Urticaria—Epirubicin—hematologic cancer	1.67e-05	5.93e-05	CcSEcCtD
Modafinil—Constipation—Doxorubicin—hematologic cancer	1.66e-05	5.91e-05	CcSEcCtD
Modafinil—Pain—Doxorubicin—hematologic cancer	1.66e-05	5.91e-05	CcSEcCtD
Modafinil—Body temperature increased—Epirubicin—hematologic cancer	1.66e-05	5.9e-05	CcSEcCtD
Modafinil—Abdominal pain—Epirubicin—hematologic cancer	1.66e-05	5.9e-05	CcSEcCtD
Modafinil—Hypersensitivity—Methotrexate—hematologic cancer	1.65e-05	5.88e-05	CcSEcCtD
Modafinil—Asthenia—Methotrexate—hematologic cancer	1.61e-05	5.73e-05	CcSEcCtD
Modafinil—Feeling abnormal—Doxorubicin—hematologic cancer	1.6e-05	5.69e-05	CcSEcCtD
Modafinil—Nausea—Prednisone—hematologic cancer	1.59e-05	5.67e-05	CcSEcCtD
Modafinil—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.59e-05	5.65e-05	CcSEcCtD
Modafinil—Pruritus—Methotrexate—hematologic cancer	1.59e-05	5.65e-05	CcSEcCtD
Modafinil—Hypersensitivity—Epirubicin—hematologic cancer	1.54e-05	5.5e-05	CcSEcCtD
Modafinil—Urticaria—Doxorubicin—hematologic cancer	1.54e-05	5.49e-05	CcSEcCtD
Modafinil—Abdominal pain—Doxorubicin—hematologic cancer	1.53e-05	5.46e-05	CcSEcCtD
Modafinil—Body temperature increased—Doxorubicin—hematologic cancer	1.53e-05	5.46e-05	CcSEcCtD
Modafinil—Diarrhoea—Methotrexate—hematologic cancer	1.53e-05	5.46e-05	CcSEcCtD
Modafinil—Asthenia—Epirubicin—hematologic cancer	1.5e-05	5.36e-05	CcSEcCtD
Modafinil—Pruritus—Epirubicin—hematologic cancer	1.48e-05	5.28e-05	CcSEcCtD
Modafinil—Dizziness—Methotrexate—hematologic cancer	1.48e-05	5.28e-05	CcSEcCtD
Modafinil—Diarrhoea—Epirubicin—hematologic cancer	1.43e-05	5.11e-05	CcSEcCtD
Modafinil—Hypersensitivity—Doxorubicin—hematologic cancer	1.43e-05	5.09e-05	CcSEcCtD
Modafinil—Vomiting—Methotrexate—hematologic cancer	1.42e-05	5.07e-05	CcSEcCtD
Modafinil—Rash—Methotrexate—hematologic cancer	1.41e-05	5.03e-05	CcSEcCtD
Modafinil—Dermatitis—Methotrexate—hematologic cancer	1.41e-05	5.03e-05	CcSEcCtD
Modafinil—Headache—Methotrexate—hematologic cancer	1.4e-05	5e-05	CcSEcCtD
Modafinil—Asthenia—Doxorubicin—hematologic cancer	1.39e-05	4.96e-05	CcSEcCtD
Modafinil—Dizziness—Epirubicin—hematologic cancer	1.39e-05	4.94e-05	CcSEcCtD
Modafinil—Pruritus—Doxorubicin—hematologic cancer	1.37e-05	4.89e-05	CcSEcCtD
Modafinil—Vomiting—Epirubicin—hematologic cancer	1.33e-05	4.75e-05	CcSEcCtD
Modafinil—Nausea—Methotrexate—hematologic cancer	1.33e-05	4.74e-05	CcSEcCtD
Modafinil—Diarrhoea—Doxorubicin—hematologic cancer	1.33e-05	4.73e-05	CcSEcCtD
Modafinil—Rash—Epirubicin—hematologic cancer	1.32e-05	4.71e-05	CcSEcCtD
Modafinil—Dermatitis—Epirubicin—hematologic cancer	1.32e-05	4.7e-05	CcSEcCtD
Modafinil—Headache—Epirubicin—hematologic cancer	1.31e-05	4.68e-05	CcSEcCtD
Modafinil—Dizziness—Doxorubicin—hematologic cancer	1.28e-05	4.57e-05	CcSEcCtD
Modafinil—Nausea—Epirubicin—hematologic cancer	1.25e-05	4.44e-05	CcSEcCtD
Modafinil—Vomiting—Doxorubicin—hematologic cancer	1.23e-05	4.39e-05	CcSEcCtD
Modafinil—Rash—Doxorubicin—hematologic cancer	1.22e-05	4.36e-05	CcSEcCtD
Modafinil—Dermatitis—Doxorubicin—hematologic cancer	1.22e-05	4.35e-05	CcSEcCtD
Modafinil—Headache—Doxorubicin—hematologic cancer	1.22e-05	4.33e-05	CcSEcCtD
Modafinil—Nausea—Doxorubicin—hematologic cancer	1.15e-05	4.1e-05	CcSEcCtD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.12e-06	0.000139	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—PIK3CB—hematologic cancer	6.1e-06	0.000138	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—AGRN—hematologic cancer	6.08e-06	0.000138	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CDKN2B—hematologic cancer	6.07e-06	0.000137	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ABCG2—hematologic cancer	6.06e-06	0.000137	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—MTR—hematologic cancer	6.06e-06	0.000137	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—PIK3R1—hematologic cancer	6.01e-06	0.000136	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—UGT1A1—hematologic cancer	5.97e-06	0.000135	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ENO2—hematologic cancer	5.94e-06	0.000134	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.9e-06	0.000134	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CD86—hematologic cancer	5.87e-06	0.000133	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—JAK2—hematologic cancer	5.84e-06	0.000132	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.82e-06	0.000132	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CRABP1—hematologic cancer	5.81e-06	0.000131	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—SLC22A1—hematologic cancer	5.81e-06	0.000131	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTP1—hematologic cancer	5.8e-06	0.000131	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—HES1—hematologic cancer	5.79e-06	0.000131	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—IDH2—hematologic cancer	5.76e-06	0.00013	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—HMMR—hematologic cancer	5.76e-06	0.00013	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTT1—hematologic cancer	5.76e-06	0.00013	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	5.76e-06	0.00013	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	5.69e-06	0.000129	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	5.69e-06	0.000129	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.67e-06	0.000128	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTP1—hematologic cancer	5.66e-06	0.000128	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ALOX5—hematologic cancer	5.66e-06	0.000128	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—SDC1—hematologic cancer	5.63e-06	0.000127	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	5.61e-06	0.000127	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	5.61e-06	0.000127	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	5.6e-06	0.000127	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.57e-06	0.000126	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	5.54e-06	0.000125	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	5.51e-06	0.000125	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	5.49e-06	0.000124	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	5.49e-06	0.000124	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—ABCB1—hematologic cancer	5.49e-06	0.000124	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NUP98—hematologic cancer	5.48e-06	0.000124	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.42e-06	0.000123	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.38e-06	0.000122	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—ABCB1—hematologic cancer	5.36e-06	0.000121	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NCOR1—hematologic cancer	5.33e-06	0.000121	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTM1—hematologic cancer	5.33e-06	0.000121	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ADCY7—hematologic cancer	5.32e-06	0.00012	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NCOA3—hematologic cancer	5.32e-06	0.00012	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.31e-06	0.00012	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NUP214—hematologic cancer	5.28e-06	0.00012	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ACP5—hematologic cancer	5.27e-06	0.000119	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CA9—hematologic cancer	5.27e-06	0.000119	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CD44—hematologic cancer	5.25e-06	0.000119	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NQO1—hematologic cancer	5.25e-06	0.000119	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	5.23e-06	0.000118	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTM1—hematologic cancer	5.21e-06	0.000118	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NCOR1—hematologic cancer	5.21e-06	0.000118	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.2e-06	0.000118	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ABCG2—hematologic cancer	5.18e-06	0.000117	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—MTR—hematologic cancer	5.18e-06	0.000117	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.14e-06	0.000116	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	5.13e-06	0.000116	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	5.09e-06	0.000115	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.08e-06	0.000115	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ENO2—hematologic cancer	5.08e-06	0.000115	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TERT—hematologic cancer	5.07e-06	0.000115	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CYCS—hematologic cancer	4.97e-06	0.000112	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—IDH1—hematologic cancer	4.96e-06	0.000112	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	4.95e-06	0.000112	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	4.94e-06	0.000112	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTT1—hematologic cancer	4.92e-06	0.000111	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—TXN—hematologic cancer	4.9e-06	0.000111	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.9e-06	0.000111	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.9e-06	0.000111	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.85e-06	0.00011	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	4.84e-06	0.00011	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—SDC1—hematologic cancer	4.81e-06	0.000109	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.8e-06	0.000109	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CD44—hematologic cancer	4.79e-06	0.000108	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NQO1—hematologic cancer	4.79e-06	0.000108	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—MTHFR—hematologic cancer	4.71e-06	0.000107	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.69e-06	0.000106	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	4.65e-06	0.000105	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	4.61e-06	0.000104	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.61e-06	0.000104	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—MTHFR—hematologic cancer	4.6e-06	0.000104	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.6e-06	0.000104	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.54e-06	0.000103	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CYCS—hematologic cancer	4.53e-06	0.000103	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	4.52e-06	0.000102	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	4.5e-06	0.000102	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.48e-06	0.000101	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.48e-06	0.000101	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FN1—hematologic cancer	4.47e-06	0.000101	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.44e-06	0.000101	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—BAD—hematologic cancer	4.41e-06	9.99e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	4.41e-06	9.99e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTP1—hematologic cancer	4.38e-06	9.91e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	4.37e-06	9.89e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.37e-06	9.89e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.34e-06	9.83e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CD80—hematologic cancer	4.28e-06	9.69e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—KIT—hematologic cancer	4.27e-06	9.67e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	4.27e-06	9.67e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	4.27e-06	9.67e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.24e-06	9.59e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NUP98—hematologic cancer	4.23e-06	9.58e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	4.2e-06	9.5e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—ABCB1—hematologic cancer	4.15e-06	9.38e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.11e-06	9.3e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.11e-06	9.3e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	4.09e-06	9.26e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NQO1—hematologic cancer	4.09e-06	9.26e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CD44—hematologic cancer	4.09e-06	9.26e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NUP214—hematologic cancer	4.08e-06	9.23e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	4.07e-06	9.21e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.05e-06	9.17e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.02e-06	9.11e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.02e-06	9.11e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	4.02e-06	9.09e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.01e-06	9.07e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.99e-06	9.04e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—MTR—hematologic cancer	3.99e-06	9.04e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTP1—hematologic cancer	3.99e-06	9.04e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	3.98e-06	9.01e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	3.97e-06	8.98e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	3.96e-06	8.97e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PIK3CG—hematologic cancer	3.95e-06	8.95e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ENO2—hematologic cancer	3.92e-06	8.87e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CYCS—hematologic cancer	3.87e-06	8.76e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PIK3CG—hematologic cancer	3.87e-06	8.75e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.86e-06	8.75e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	3.85e-06	8.71e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.8e-06	8.6e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	3.78e-06	8.56e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ABCB1—hematologic cancer	3.78e-06	8.56e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	3.76e-06	8.5e-05	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	3.72e-06	8.42e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—SDC1—hematologic cancer	3.71e-06	8.41e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	3.68e-06	8.33e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NCOR1—hematologic cancer	3.67e-06	8.31e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTM1—hematologic cancer	3.67e-06	8.31e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CREBBP—hematologic cancer	3.67e-06	8.3e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	3.6e-06	8.14e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CREBBP—hematologic cancer	3.58e-06	8.11e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—MTHFR—hematologic cancer	3.56e-06	8.05e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	3.55e-06	8.03e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PIK3CD—hematologic cancer	3.48e-06	7.87e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.46e-06	7.84e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	3.45e-06	7.81e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—ALB—hematologic cancer	3.43e-06	7.77e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTP1—hematologic cancer	3.41e-06	7.72e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PIK3CD—hematologic cancer	3.4e-06	7.69e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	3.38e-06	7.65e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	3.37e-06	7.62e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—ALB—hematologic cancer	3.35e-06	7.59e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.3e-06	7.47e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PIK3R1—hematologic cancer	3.28e-06	7.43e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	3.27e-06	7.41e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	3.27e-06	7.41e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.24e-06	7.34e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ABCB1—hematologic cancer	3.23e-06	7.31e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PIK3R1—hematologic cancer	3.21e-06	7.26e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CD44—hematologic cancer	3.16e-06	7.15e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NQO1—hematologic cancer	3.16e-06	7.15e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTM1—hematologic cancer	3.14e-06	7.1e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NCOR1—hematologic cancer	3.14e-06	7.1e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.13e-06	7.1e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	3.13e-06	7.08e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	3.07e-06	6.96e-05	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	3.04e-06	6.88e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PIK3CB—hematologic cancer	3.03e-06	6.86e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	3.01e-06	6.82e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL2—hematologic cancer	3.01e-06	6.81e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	2.99e-06	6.77e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.99e-06	6.76e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CYCS—hematologic cancer	2.99e-06	6.76e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.97e-06	6.72e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PIK3CB—hematologic cancer	2.96e-06	6.7e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	2.93e-06	6.64e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JUN—hematologic cancer	2.93e-06	6.62e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.86e-06	6.47e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	2.84e-06	6.42e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	2.83e-06	6.41e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.77e-06	6.27e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.77e-06	6.27e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	2.77e-06	6.27e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	2.76e-06	6.25e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.72e-06	6.17e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—EP300—hematologic cancer	2.7e-06	6.11e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.63e-06	5.96e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.63e-06	5.95e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—SRC—hematologic cancer	2.62e-06	5.94e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PTEN—hematologic cancer	2.62e-06	5.93e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—ALB—hematologic cancer	2.59e-06	5.87e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PTEN—hematologic cancer	2.56e-06	5.79e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	2.56e-06	5.79e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	2.53e-06	5.73e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.53e-06	5.72e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	2.52e-06	5.71e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—EP300—hematologic cancer	2.5e-06	5.65e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.49e-06	5.64e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.48e-06	5.62e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.44e-06	5.53e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—EP300—hematologic cancer	2.44e-06	5.53e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.42e-06	5.48e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.42e-06	5.48e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.42e-06	5.47e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.4e-06	5.42e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ALB—hematologic cancer	2.36e-06	5.35e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.35e-06	5.32e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.35e-06	5.31e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.33e-06	5.27e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.29e-06	5.18e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.26e-06	5.12e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.17e-06	4.92e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.16e-06	4.89e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.14e-06	4.84e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.09e-06	4.73e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.05e-06	4.63e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ALB—hematologic cancer	2.02e-06	4.57e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2e-06	4.52e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PTEN—hematologic cancer	1.98e-06	4.48e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.93e-06	4.38e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TP53—hematologic cancer	1.93e-06	4.37e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—EP300—hematologic cancer	1.89e-06	4.27e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.85e-06	4.18e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	1.85e-06	4.18e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.81e-06	4.09e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PTEN—hematologic cancer	1.8e-06	4.08e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.8e-06	4.07e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.78e-06	4.04e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL6—hematologic cancer	1.77e-06	4e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—EP300—hematologic cancer	1.72e-06	3.89e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.67e-06	3.77e-05	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	1.63e-06	3.69e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.58e-06	3.58e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ALB—hematologic cancer	1.56e-06	3.53e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PTEN—hematologic cancer	1.54e-06	3.49e-05	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—AKT1—hematologic cancer	1.51e-06	3.42e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.49e-06	3.38e-05	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—AKT1—hematologic cancer	1.48e-06	3.34e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—EP300—hematologic cancer	1.47e-06	3.33e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.4e-06	3.16e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.38e-06	3.12e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.27e-06	2.88e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PTEN—hematologic cancer	1.19e-06	2.69e-05	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—AKT1—hematologic cancer	1.14e-06	2.58e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—EP300—hematologic cancer	1.13e-06	2.57e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.09e-06	2.46e-05	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—AKT1—hematologic cancer	1.04e-06	2.35e-05	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—AKT1—hematologic cancer	8.89e-07	2.01e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.39e-07	1.9e-05	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—AKT1—hematologic cancer	6.86e-07	1.55e-05	CbGpPWpGaD
